Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › nemolizumab

nemolizumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of nemolizumab

12 trials tracked of nemolizumab: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 163 citations.

12Trials tracked
5Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 5 Phase 2 6 Phase 1 1
  1. Phase 3 A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Completed · 163 cited
  2. Phase 3 Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Completed · 124 cited
  3. Phase 3 Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Completed · 119 cited
  4. Phase 3 A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis Completed
  5. Phase 3 To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus Completed
  6. Phase 2 A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis Completed
Show 6 more trials
  1. Phase 2 Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis Completed
  2. Phase 2 A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab Completed
  3. Phase 2 An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis Completed
  4. Phase 2 A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD) Completed
  5. Phase 2 Dose-ranging Study of Nemolizumab in Atopic Dermatitis Completed
  6. Phase 1 Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Nemolizumab Q4W improves IGA success maintenance by 11.8% over withdrawal in atopic dermatitis
Dermatology RCT
Nemolizumab Q4W improves IGA success maintenance by 11.8% over withdrawal in atopic dermatitis Trial shows nemolizumab maintains skin results for atopic dermatitis
This Phase 3 randomized controlled trial evaluated nemolizumab in 507 adolescents and adults with moderate-to-severe atopic dermatitis who w…
A new trial found that nemolizumab helps maintain clear skin and reduce itching for adults and teens with moderate to severe atopic dermatit…
Jun 13, 2026
Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy
Neurology Meta-analysis
Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy Dupilumab and Pimecrolimus Lead New Rankings for Children's Eczema Relief
This network meta-analysis evaluated dupilumab, pimecrolimus, melatonin, probiotics, tralokinumab, nemolizumab, and vitamin D for pediatric …
A new analysis ranks the top treatments for children's eczema, with dupilumab and pimecrolimus leading for symptom relief.
Frontiers May 2, 2026